Table 2.

Mean ± SD pharmacokinetic parameter estimates

	PF-05280014	Trastuzumab-EU	Trastuzumab-US
Subjects (n)	34	35	32
Cmax (μg ml−1)	159 ± 26	174 ± 31	164 ± 31
(μg ml−1 h)*	35700 ± 6287	38510 ± 6569	35870 ± 6878
AUC(0,∞) (μg ml−1 h)	37130 ± 6305	40330 ± 6994	37310 ± 6728
CL (ml h−1 kg−1)	0.166 ± 0.026	0.153 ± 0.025	0.166 ± 0.032
Vss (ml kg−1)	56.1 ± 8.2	51.7 ± 6.9	55.7 ± 8.8
t1/2 (h)	213 ± 42	220 ± 42	212 ± 47

^* was ≥80% of corresponding AUC_(0,∞) in all PK eligible subjects. , area under the concentration–time curve from time 0 to last time point of measurable concentration; AUC_(0,∞), area under the concentration–time curve from time 0 extrapolated to infinite time; CL, clearance; C_max, maximum drug concentration; SD, standard deviation; t_1/2, terminal half-life; V_ss, volume of distribution at steady-state.